Search

Your search keyword '"Wirjanata, Grennady"' showing total 127 results

Search Constraints

Start Over You searched for: Author "Wirjanata, Grennady" Remove constraint Author: "Wirjanata, Grennady"
127 results on '"Wirjanata, Grennady"'

Search Results

3. On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity

4. Longitudinal ex vivo and molecular trends of chloroquine and piperaquine activity against Plasmodium falciparum and P. vivax before and after introduction of artemisinin-based combination therapy in Papua, Indonesia

5. Sterile protection againstP. vivaxmalaria by repeated blood stage infection in theAotusmonkey model

6. Author Reply to Peer Reviews of Sterile protection against Plasmodium vivax malaria by repeated blood stage infection in the Aotus monkey model

8. On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity

10. A novel multiple-stage antimalarial agent that inhibits protein synthesis

11. KAF156 Is an Antimalarial Clinical Candidate with Potential for Use in Prophylaxis, Treatment, and Prevention of Disease Transmission

14. RepeatedPlasmodium vivaxblood stage infection provides sterile protection against homologous challenge in non-human primates

15. Short tandem repeat polymorphism in the promoter region of cyclophilin 19B drives its transcriptional upregulation and contributes to drug resistance in the malaria parasite Plasmodium falciparum

16. Identification of an Inhibitory Pocket in Falcilysin Bound by Chloroquine Provides a New Avenue for Malaria Drug Development

17. The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance

18. Identification of an inhibitory pocket in falcilysin bound by chloroquine provides a new avenue for malaria drug development

19. Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling

21. Molecular surveillance over 14 years confirms reduction of Plasmodium vivax and falciparum transmission after implementation of Artemisinin-based combination therapy in Papua, Indonesia

22. A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance

23. Corrigendum: A novel multiple-stage antimalarial agent that inhibits protein synthesis

24. 3,3′-Disubstituted 5,5′-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity

26. Erratum for Brunschwig et al., “UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria”

27. Plasmodium falciparum and Plasmodium vivax Demonstrate Contrasting Chloroquine Resistance Reversal Phenotypes

28. UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria

29. Passively versus Actively Detected Malaria: Similar Genetic Diversity but Different Complexity of Infection

30. A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance

31. Submicroscopic and Asymptomatic Plasmodium Parasitaemia Associated with Significant Risk of Anaemia in Papua, Indonesia

32. A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria

33. Erratum: Corrigendum: A novel multiple-stage antimalarial agent that inhibits protein synthesis

34. Analysis of ex vivo drug response data of Plasmodium clinical isolates: the pros and cons of different computer programs and online platforms

36. Quantification of Plasmodium ex vivo drug susceptibility by flow cytometry

37. Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum

38. Quinolone-3-Diarylethers: A New Class of Antimalarial Drug

39. Effective Preparation of Plasmodium vivax Field Isolates for High-Throughput Whole Genome Sequencing

40. Comparative Ex Vivo Activity of Novel Endoperoxides in Multidrug-Resistant Plasmodium falciparum and P. vivax

41. Expression of Plasmodium vivaxcrt-oIs Related to Parasite Stage but Not Ex VivoChloroquine Susceptibility

42. Potent Ex VivoActivity of Naphthoquine and Methylene Blue against Drug-Resistant Clinical Isolates of Plasmodium falciparumand Plasmodium vivax

43. Contrasting Ex VivoEfficacies of “Reversed Chloroquine” Compounds in Chloroquine-Resistant Plasmodium falciparumand P. vivaxIsolates

44. Effective Preparation of Plasmodium vivaxField Isolates for High-Throughput Whole Genome Sequencing.

45. Comparative Ex VivoActivity of Novel Endoperoxides in Multidrug-Resistant Plasmodium falciparumand P. vivax

46. The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparumparasite resistance

47. Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose–Efficacy Modeling

48. Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose–Efficacy Modeling

49. Erratum for Brunschwig et al., “UCT943, a Next-Generation Plasmodium falciparumPI4K Inhibitor Preclinical Candidate for the Treatment of Malaria”

50. UCT943, a Next-Generation Plasmodium falciparumPI4K Inhibitor Preclinical Candidate for the Treatment of Malaria

Catalog

Books, media, physical & digital resources